Special Issue "Nanotechnology for Drug and Gene Delivery"
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 1420
The advent of nanotechnology has led to the development of novel diagnostic and therapeutic strategies capable of changing how we treat cancer. The properties of nanotechnology can be harnessed to design diagnostic tools that enable the earlier detection and precise monitoring of patient responses to treatment, thus potentially enhancing patient outcomes. Nanotechnology also provides the means to target therapeutic agents both selectively and directly to neoplastic niches, thus enabling the safer delivery of radiotherapy, chemotherapy, and targeted therapies. The benefits of nanomaterials for cancer thus depend on their ability 1) to be easily functionalized an engineered, 2) to act as theranostic (i.e., diagnostic and therapeutic) platforms, 2) to passively accumulate at cancer sites through the EPR effect, 3) to be actively and selectively targeted to tumor cells while avoiding the side effects of traditional therapeutic modalities and 4) to overcome the traditional biological barriers, including the blood–brain barrier or the dense stroma of pancreatic cancer. In this Special Issue, we will explore the various applications of nanotechnology to cancer treatment. We will discuss the latest advances in 1) the application of nanotechnology in cancer detection and diagnosis and 2) nanotherapeutic solutions for cancer treatment including nano-enabled chemotherapy, radiotherapy, immune and targeted therapies, and gene delivery. We will also examine how nanotherapeutic approaches can be used to reprogram the tumor microenvironment to overcome drug resistance. Finally, we will review the current nanotechnology clinical trials.
Dr. Batoul Farran
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug and gene delivery
- cancer therapy